A Phase III Randomized, Double-blind Trial Investigating the Activity of Dolutegravir 50 mg BID vs Placebo Over 7 Days in HIV-1-infected Subjects With RAL/ELV Resistance, Followed by an Open-label Phase With an Optimized Background Regimen.

Trial Profile

A Phase III Randomized, Double-blind Trial Investigating the Activity of Dolutegravir 50 mg BID vs Placebo Over 7 Days in HIV-1-infected Subjects With RAL/ELV Resistance, Followed by an Open-label Phase With an Optimized Background Regimen.

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 16 Oct 2014

At a glance

  • Drugs Dolutegravir (Primary) ; Antiretrovirals; Integrase inhibitors
  • Indications HIV-1 infections
  • Focus Therapeutic Use
  • Acronyms VIKING-4
  • Sponsors ViiV Healthcare
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 21 Nov 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
    • 14 Sep 2012 Planned End Date changed from 1 Nov 2012 to 1 Jun 2015 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top